These results suggest that the inhibition of PKM2 can enhance the inhibition of ovarian cancer cell growth by suppressing aerobic glycolysis, which provides a basis for the development of PKM2-targeted therapies for ovarian cancer through PKM2 overexpression. This evidence concerns the gene PKM and ovarian cancer.